Vanguard reports 7.68M NeoGenomics shares (5.91%)
Vanguard Portfolio Management reports beneficial ownership of 7,677,794 shares of NeoGenomics Inc. under Schedule 13G, representing 5.91% of the outstanding common stock as reported.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Vanguard Portfolio Management reports beneficial ownership of 7,677,794 shares of NeoGenomics Inc. under Schedule 13G, representing 5.91% of the outstanding common stock as reported. The filing shows Vanguard has 55,607 shares with sole voting power and 7,677,794 shares with sole dispositive power.
The disclosure lists the issuer CUSIP 64049M209 and identifies Vanguard affiliates included in the reporting group. Signature is by Ashley Grim, Head of Global Fund Administration, dated 04/29/2026.
Key Figures
Key Terms
Schedule 13G regulatory
beneficially owned regulatory
sole dispositive power regulatory
reporting group affiliates other
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of NeoGenomics (NEO) does Vanguard Portfolio Management hold?
Which Vanguard entities are included in the Schedule 13G filing for NEO?
What CUSIP and issuer details are given in the filing for NeoGenomics?
AI-generated analysis. How Rhea-AI works. Not financial advice.